Portal de Periódicos da CAPES

INDUCTION OF PROSTATE APOPTOSIS BY DOXAZOSIN IN BENIGN PROSTATIC HYPERPLASIA

1998; Lippincott Williams & Wilkins; Volume: 159; Issue: 6 Linguagem: Inglês

10.1016/s0022-5347(01)63162-8

1527-3792

Natasha Kyprianou, Juan P. Litvak, Andrew Borkowski, Richard B. Alexander, Stephen C. Jacobs,

Protein Interaction Studies and Fluorescence Analysis

No AccessJournal of UrologyClinical Urology: Original Articles1 Jun 1998INDUCTION OF PROSTATE APOPTOSIS BY DOXAZOSIN IN BENIGN PROSTATIC HYPERPLASIA NATASHA KYPRIANOU, JUAN P. LITVAK, ANDREW BORKOWSKI, RICHARD ALEXANDER, and STEPHEN C. JACOBS NATASHA KYPRIANOUNATASHA KYPRIANOU , JUAN P. LITVAKJUAN P. LITVAK , ANDREW BORKOWSKIANDREW BORKOWSKI , RICHARD ALEXANDERRICHARD ALEXANDER , and STEPHEN C. JACOBSSTEPHEN C. JACOBS View All Author Informationhttps://doi.org/10.1016/S0022-5347(01)63162-8AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: The molecular mechanisms underlying the therapeutic effect of the alpha 1 blocker, doxazosin, on benign prostatic hyperplasia (BPH) are poorly understood. We evaluated the effect of doxazosin on cell proliferation and apoptosis in the prostatic glandular epithelium and stroma of patients with BPH. Materials and Methods: We examined proliferative and apoptotic activities in prostate specimens of 22 men a mean of 65 years old with BPH before and after doxazosin treatment within the normal therapeutic range. Proliferative and apoptotic indexes were determined using Ki-67 nuclear antigen staining and the terminal transferase end labeling assay, respectively. The smooth muscle cell content in prostatic specimens was identified by smooth muscle alpha-actin, and desmin immunoreactivity and apoptotic indexes were correlated with prostatic stromal tissue regression and improvement in BPH symptoms. Results: In response to doxazosin treatment there were no significant changes in the kinetics of cell proliferation in the prostatic epithelial or stromal cell population. Mean pretreatment baseline apoptosis was 1.9 and 1.0% for the epithelial and stromal prostate components, respectively. Mean apoptotic indexes significantly increased after 3 months of doxazosin treatment in the glandular epithelial (6%) and smooth muscle cells (15%). By 12 months after treatment epithelial apoptosis had decreased to constitutive levels, while the apoptotic index of prostatic stroma cells remained high. Doxazosin induced smooth muscle cell apoptosis correlated with prostatic stromal degeneration, decreased alpha-smooth muscle actin expression and improved BPH symptoms. Conclusions: These findings implicate the induction of prostate apoptosis by doxazosin as a potential molecular mechanism underlying the acute and chronic therapeutic responses of BPH to alpha 1 blockade. References 1 : Benign prostatic hyperplasia: etiological considerations. In: Approaches to the Study of Benign Prostatic Hyperplasia. Edited by . New York: Liss1984: 10. Google Scholar 2 : Benign prostatic hyperplasia: a review of its histogenesis and natural history. Prostate, suppl.1996; 6: 67. Crossref, Medline, Google Scholar 3 : The development of human benign prostatic hyperplasia with age. J. Urol.1984; 132: 474. Link, Google Scholar 4 : Etiology and disease process of benign prostatic hyperplasia. Prostate, suppl.1989; 2: 33. Crossref, Medline, Google Scholar 5 : The use of alpha-adrenergic blockers in benign prostatic obstruction. Brit. J. Urol.1976; 48: 255. Medline, Google Scholar 6 : Adrenergic and cholinergic receptors in the human prostate, prostatic capsule and bladder neck. Brit. J. Urol.1975; 47: 193. Crossref, Medline, Google Scholar 7 : Medical management of benign prostatic hyperplasia with androgen suppression. Prostate, suppl.1990; 3: 49. Crossref, Medline, Google Scholar 8 : Role of long-acting selective alpha-1 blockers in the treatment of benign prostatic hyperplasia. Urol. Clin. N. Amer.1990; 17: 651. Medline, Google Scholar 9 : The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. New Engl. J. Med.1992; 327: 1185. Crossref, Medline, Google Scholar 10 : The effect of nafarelin acetate, a luteinizing-hormone-releasing hormone agonist, on benign prostatic hyperplasia. New Engl. J. Med.1987; 317: 599. Crossref, Medline, Google Scholar 11 : The alpha-adrenereceptor subtype mediating the tension of human prostatic smooth muscle. Prostate1993; 22: 301. Crossref, Medline, Google Scholar 12 : Role of alpha-adrenergic blockers in the treatment of benign prostatic hyperplasia. Prostate, suppl.1990; 3: 75. Crossref, Medline, Google Scholar 13 : for the Multicenter Study Group: Doxazosin in the treatment of benign prostatic hyperplasia in normotensive patients: a multicenter study. J. Urol.1995; 154: 105. Link, Google Scholar 14 : for the Multicenter Study Group: Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension: a double-blind, placebo-controlled, dose response multicenter study. J. Urol.1995; 154: 110. Link, Google Scholar 15 : Apoptosis: mechanisms and roles in pathology. Int. Rev. Exp. Path.1991; 32: 233. Google Scholar 16 : Implication of cell cycle kinetic changes during the progression of human prostate cancer. Clin. Cancer Res.1995; 1: 473. Medline, Google Scholar 17 : Apoptotic versus proliferative activities in human benign prostatic hyperplasia. Hum. Path.1996; 27: 668. Crossref, Medline, Google Scholar 18 : Bcl-2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc. Natl. Acad. Sci.1991; 88: 6961. Crossref, Medline, Google Scholar 19 : Pathology of benign prostatic hyperplasia: insight into etiology. Urol. Clin. N. Amer.1990; 17: 477. Crossref, Medline, Google Scholar 20 : Benign prostatic hyperplasia. In: Campbell's Urology. Edited by . Philadelphia: W. B. Saunders Co.1992: 1009. Google Scholar 21 : A monoclonal antibody against alpha-smooth muscle actin: a new probe for smooth muscle differentiation. J. Cell. Biol.1986; 103: 2787. Crossref, Medline, Google Scholar 22 : Human prostatic smooth muscle cells in culture: estradiol enhances expression of smooth muscle cell-specific markers. Prostate1997; 30: 117. Crossref, Medline, Google Scholar 23 : Antibodies to different intermediate filament proteins. Cell type specific markers on parrafin-embedded human tissue. Lab. Invest.1981; 45: 427. Medline, Google Scholar 24 : Quantifying the smooth muscle content of the prostate using double-immunoenzymatic staining and color assisted image analysis. J. Urol.1992; 147: 1167. Link, Google Scholar 25 : The response to alpha blockade in benign prostatic hyperplasia is related to the percent area density of prostate smooth muscle. Prostate1992; 21: 297. Crossref, Medline, Google Scholar 26 : Transforming growth factor beta 1 transduced mouse prostate reconstitutions: II. Induction of apoptosis by doxazosin. Prostate1997; 33: 157. Crossref, Medline, Google Scholar 27 : Prostatic alpha 1-adrenoceptors and uroselectivity. Prostate1997; 30: 202. Crossref, Medline, Google Scholar 28 : Characterization of alpha1 adrenergic receptors in human benign prostatic hyperplasia. J. Urol.1984; 132: 1226. Link, Google Scholar 29 : Identification, quantification and localization of mRNA for three distinct alpha1 adrenergic receptor subtypes in human prostate. J. Urol.1993; 150: 546. Link, Google Scholar 30 : Evolving patterns of tissue composition in benign prostatic hyperplasia as a function of specimen size. Hum. Path.1990; 21: 578. Crossref, Medline, Google Scholar 31 : The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. New Engl. J. Med.1996; 335: 533. Crossref, Medline, Google Scholar 32 : Activation of programmed cell death in the rat ventral prostate after castration. Endocrinology1988; 122: 552. Crossref, Medline, Google Scholar 33 : Prostatic involution in rats induced by a novel 5 alpha-reductase inhibitor, SK&F 105657: role for testosterone in the androgenic response. Endocrinology1992; 130: 685. Medline, Google Scholar 34 : Evidence for atrophy and apoptosis in the ventral prostate of rats given the 5 alpha-reductase inhibitor finasteride. Endocrinology1995; 136: 741. Crossref, Medline, Google Scholar From the Division of Urology and Departments of Biochemistry and Molecular Biology, and Pathology, University of Maryland School of Medicine, Baltimore, Maryland© 1998 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited by Medina-Pizaño M, Medina-Rosales M, Martínez-Hernández S, Aldaba-Muruato L, Macías-Pérez J, Sánchez-Alemán E, Ventura-Juárez J, Muñoz-Ortega M and Borrás C (2022) Protective Effect of Curcumin against Doxazosin- and Carvedilol-Induced Oxidative Stress in HepG2 CellsOxidative Medicine and Cellular Longevity, 10.1155/2022/6085515, VOL. 2022, (1-15), Online publication date: 11-Feb-2022. Huang R, Liu Y, Ciotkowska A, Tamalunas A, Waidelich R, Strittmatter F, Stief C and Hennenberg M (2021) Concentration-dependent alpha1-Adrenoceptor Antagonism and Inhibition of Neurogenic Smooth Muscle Contraction by Mirabegron in the Human ProstateFrontiers in Pharmacology, 10.3389/fphar.2021.666047, VOL. 12 King L, Christie D, Dare W, Bernaitis N, Chess-Williams R, McDermott C, Forbes A and Anoopkumar-Dukie S (2021) Quinazoline alpha-adrenoreceptor blockers as an adjunct cancer treatment: From bench to bedsideEuropean Journal of Pharmacology, 10.1016/j.ejphar.2020.173831, VOL. 893, (173831), Online publication date: 1-Feb-2021. Xiao Q, Liu Q, Jiang R, Chen K, Zhu X, Ma L, Li W, He F and Huang J (2021) Piperazine-Derived α1D/1A Antagonist 1- Benzyl-N- (3-(4- (2-Methoxyphenyl) Piperazine-1-yl) Propyl) -1H- Indole-2- Carboxamide Induces Apoptosis in Benign Prostatic Hyperplasia Independently of α1-Adrenoceptor BlockingFrontiers in Pharmacology, 10.3389/fphar.2020.594038, VOL. 11 Liu Q, Xiao Q, Zhu X, Chen K, Liu X, Jiang R, Wu D, Shi J, Dai L and Huang J (2020) Inhibitory effect of α1D/1A antagonist 2-(1H-indol-3-yl)-N-[3-(4-(2-methoxyphenyl) piperazinyl) propyl] acetamide on estrogen/androgen-induced rat benign prostatic hyperplasia model in vivoEuropean Journal of Pharmacology, 10.1016/j.ejphar.2019.172817, VOL. 870, (172817), Online publication date: 1-Mar-2020. Good D, Nahas B, Phipps S, Popert R, Stolzenburg J and McNeill S (2019) Prostate Benign Prostatic Hyperplasia Blandy's Urology, 10.1002/9781118863343.ch27, (531-561), Online publication date: 22-Mar-2019. Vishnuvardhan C, Saibaba B, Allakonda L, Swain D, Gananadhamu S, Srinivas R and Satheeshkumar N (2017) LC–ESI–MS/MS evaluation of forced degradation behaviour of silodosin: In vitro anti cancer activity evaluation of silodosin and major degradation productsJournal of Pharmaceutical and Biomedical Analysis, 10.1016/j.jpba.2016.11.013, VOL. 134, (1-10), Online publication date: 1-Feb-2017. Forbes A, Anoopkumar-Dukie S, Chess-Williams R and McDermott C (2016) Relative cytotoxic potencies and cell death mechanisms of α 1 -adrenoceptor antagonists in prostate cancer cell lines The Prostate, 10.1002/pros.23167, VOL. 76, NO. 8, (757-766), Online publication date: 1-Jun-2016. Wu F, Ding S, Li X, Wang H, Liu S, Wu H, Bi D, Ding K and Lu J (2016) Elevated expression of HIF-lα in actively growing prostate tissues is associated with clinical features of benign prostatic hyperplasiaOncotarget, 10.18632/oncotarget.7641, VOL. 7, NO. 11, (12053-12062), Online publication date: 15-Mar-2016. Jeon E, Chung K and An H (2016) Anti-proliferation effects of Cistanches salsa on the progression of benign prostatic hyperplasia Canadian Journal of Physiology and Pharmacology, 10.1139/cjpp-2015-0112, VOL. 94, NO. 1, (104-111), Online publication date: 1-Jan-2016. Holmström F, Shimizu S, Shimizu T, Higashi Y, Martin D, Honda M and Saito M (2015) Protective effect of hydroxyfasudil, a Rho kinase inhibitor, on ventral prostatic hyperplasia in the spontaneously hypertensive ratThe Prostate, 10.1002/pros.23063, VOL. 75, NO. 15, (1774-1782), Online publication date: 1-Nov-2015. Shimizu S, Shimizu T, Tsounapi P, Higashi Y, Martin D, Nakamura K, Honda M, Inoue K, Saito M and Ahmed A (2015) Effect of Silodosin, an Alpha1A-Adrenoceptor Antagonist, on Ventral Prostatic Hyperplasia in the Spontaneously Hypertensive RatPLOS ONE, 10.1371/journal.pone.0133798, VOL. 10, NO. 8, (e0133798) Patil K, McPherson L and Daly C (2015) Co-Localization of Alpha1-Adrenoceptors and GPR55: A Novel Prostate Cancer Paradigm?Pharmacology & Pharmacy, 10.4236/pp.2015.64023, VOL. 06, NO. 04, (212-220), . François N, Patel R and McVary K (2014) α-Adrenergic Antagonists for Lower Urinary Symptoms Secondary to Benign Prostatic Hyperplasia Male Lower Urinary Tract Symptoms and Benign Prostatic Hyperplasia, 10.1002/9781118437889.ch7, (70-89) Hennenberg M, Stief C and Gratzke C (2013) Prostatic α1-adrenoceptors: New concepts of function, regulation, and intracellular signalingNeurourology and Urodynamics, 10.1002/nau.22467, VOL. 33, NO. 7, (1074-1085), Online publication date: 1-Sep-2014. Saito M, Tsounapi P, Oikawa R, Shimizu S, Honda M, Sejima T, Kinoshita Y and Tomita S (2014) Prostatic ischemia induces ventral prostatic hyperplasia in the SHR; possible mechanism of development of BPHScientific Reports, 10.1038/srep03822, VOL. 4, NO. 1 Chen Y, Palczewska G, Mustafi D, Golczak M, Dong Z, Sawada O, Maeda T, Maeda A and Palczewski K (2013) Systems pharmacology identifies drug targets for Stargardt disease–associated retinal degenerationJournal of Clinical Investigation, 10.1172/JCI69076, VOL. 123, NO. 12, (5119-5134), Online publication date: 2-Dec-2013. White C, Xie J and Ventura S (2014) Age-related changes in the innervation of the prostate glandOrganogenesis, 10.4161/org.24843, VOL. 9, NO. 3, (206-215), Online publication date: 1-Jul-2013. Hendrix L, Hamilton D and Kyprianou N (2014) Emerging therapeutics targeting castration-resistant prostate cancer: the AR-mageddon of tumor epithelial–mesenchymal transitionExpert Review of Endocrinology & Metabolism, 10.1586/17446651.2013.811914, VOL. 8, NO. 4, (403-416), Online publication date: 1-Jul-2013. Delella F, Lacorte L, Almeida F, Pai M and Felisbino S (2012) Fibrosis-related gene expression in the prostate is modulated by doxazosin treatmentLife Sciences, 10.1016/j.lfs.2012.09.017, VOL. 91, NO. 25-26, (1281-1287), Online publication date: 1-Dec-2012. Hennenberg M, Strittmatter F, Beckmann C, Rutz B, Füllhase C, Waidelich R, Montorsi F, Hedlund P, Andersson K, Stief C, Gratzke C and Chai K (2012) Silodosin Inhibits Noradrenaline-Activated Transcription Factors Elk1 and SRF in Human Prostate Smooth MusclePLoS ONE, 10.1371/journal.pone.0050904, VOL. 7, NO. 11, (e50904) Sahabudeen W (2012) Baus Medical Student Essay Competition: Medical Management of Symptomatic Benign Prostatic EnlargementBritish Journal of Medical and Surgical Urology, 10.1016/j.bjmsu.2012.09.001, VOL. 5, NO. 6, (297-301), Online publication date: 1-Nov-2012. Strittmatter F, Walther S, Roosen A, Rutz B, Schlenker B, Limmer S, Waidelich R, Stief C, Gratzke C and Hennenberg M (2012) Activation of protein kinase B/Akt by alpha1-adrenoceptors in the human prostateLife Sciences, 10.1016/j.lfs.2012.01.002, VOL. 90, NO. 11-12, (446-453), Online publication date: 1-Mar-2012. McNicholas T, Kirby R and Lepor H (2012) Evaluation and Nonsurgical Management of Benign Prostatic Hyperplasia Campbell-Walsh Urology, 10.1016/B978-1-4160-6911-9.00092-X, (2611-2654.e8), . Desiniotis A and Kyprianou N (2011) Advances in the design and synthesis of prazosin derivatives over the last ten yearsExpert Opinion on Therapeutic Targets, 10.1517/14728222.2011.641534, VOL. 15, NO. 12, (1405-1418), Online publication date: 1-Dec-2011. Morcos M and Afifi N (2011) Effect of doxazocin on experimentally induced prostatic hyperplasia in adult male albino ratsThe Egyptian Journal of Histology, 10.1097/01.EHX.0000407624.42021.3b, VOL. 34, NO. 4, (870-882), Online publication date: 1-Dec-2011. Karadağ E, Öner S, Budak Y and Atahan Ö (2011) Randomized crossover comparison of tamsulosin and alfuzosin in patients with urinary disturbances caused by benign prostatic hyperplasiaInternational Urology and Nephrology, 10.1007/s11255-011-9949-2, VOL. 43, NO. 4, (949-954), Online publication date: 1-Dec-2011. Strittmatter F, Gratzke C, Walther S, Göttinger J, Beckmann C, Roosen A, Schlenker B, Reich O, Stief C and Hennenberg M (2011) Alpha1-adrenoceptor Signaling in the Human Prostate Involves Regulation of p38 Mitogen-activated Protein KinaseUrology, 10.1016/j.urology.2011.03.036, VOL. 78, NO. 4, (969.e7-969.e13), Online publication date: 1-Oct-2011. Johansson M (2011) Lord of the Rings: A Promising Novel Treatment for Renal Cell Carcinoma?European Urology, 10.1016/j.eururo.2011.01.024, VOL. 59, NO. 5, (745-746), Online publication date: 1-May-2011. Delella F and Felisbino S (2010) Doxazosin treatment alters stromal cell behavior and increases elastic system fibers deposition in rat prostateMicroscopy Research and Technique, 10.1002/jemt.20828, VOL. 73, NO. 11, (1036-1044), Online publication date: 1-Oct-2010. Santaella R, Destafeno J, Stinnett S, Proia A, Chang D and Kim T (2010) The Effect of α1-Adrenergic Receptor Antagonist Tamsulosin (Flomax) on Iris Dilator Smooth Muscle AnatomyOphthalmology, 10.1016/j.ophtha.2010.01.022, VOL. 117, NO. 9, (1743-1749), Online publication date: 1-Sep-2010. Zhao X, Yuan M, Huang B, Ji H and Zhu L (2010) Ligand-based pharmacophore model of N-Aryl and N-Heteroaryl piperazine α1A-adrenoceptors antagonists using GALAHADJournal of Molecular Graphics and Modelling, 10.1016/j.jmgm.2010.05.002, VOL. 29, NO. 2, (126-136), Online publication date: 1-Sep-2010. Justulin Jr L, Acquaro C, Carvalho R, Silva M and Felisbino S (2009) Combined effect of the finasteride and doxazosin on rat ventral prostate morphology and physiologyInternational Journal of Andrology, 10.1111/j.1365-2605.2009.00963.x, VOL. 33, NO. 3, (489-499) Kyprianou N, Vaughan T and Michel M (2009) Apoptosis induction by doxazosin and other quinazoline α1-adrenoceptor antagonists: a new mechanism for cancer treatment?Naunyn-Schmiedeberg's Archives of Pharmacology, 10.1007/s00210-009-0462-4, VOL. 380, NO. 6, (473-477), Online publication date: 1-Dec-2009. Tian H, Zhao D, Ren L, Su X and Kang Y (2009) Effects of (−)Doxazosin on Histomorphologic and Cell Apoptotic Changes of the Hyperplastic Prostate in Castrated RatsThe American Journal of the Medical Sciences, 10.1097/MAJ.0b013e3181a6b14d, VOL. 338, NO. 3, (196-200), Online publication date: 1-Sep-2009. Sarramon J (2008) Re: Effect of α1-Adrenoreceptor Antagonist Exposure on Prostate Cancer Incidence: An Observational Cohort StudyEuropean Urology, 10.1016/j.eururo.2008.03.025, VOL. 53, NO. 6, (1300), Online publication date: 1-Jun-2008. Justulin L, Delella F and Felisbino S (2008) Doxazosin reduces cell proliferation and increases collagen fibers in rat prostatic lobesCell and Tissue Research, 10.1007/s00441-007-0559-3, VOL. 332, NO. 1, (171-183), Online publication date: 1-Apr-2008. Cha W, Jang T and Lee K (2008) Expression of Survivin and Bcl-2 in Benign Prostatic Hyperplasia Treated with a 5-alpha-reductase InhibitorKorean Journal of Urology, 10.4111/kju.2008.49.3.242, VOL. 49, NO. 3, (242), . Paick J, Cho M, Song S, Kim S and Ku J (2008) Impacts of the Quinazoline-Based Alpha1-Antagonist, Terazosin, and of the Sulfonamide Derivative, Tamsulosin, on Serum Prostate-Specific Antigen and Prostate VolumeJournal of Korean Medical Science, 10.3346/jkms.2008.23.3.509, VOL. 23, NO. 3, (509), . Harris A, Warner B, Wilson J, Becker A, Rowland R, Conner W, Lane M, Kimbler K, Durbin E, Baron A and Kyprianou N (2007) Effect of α1-Adrenoceptor Antagonist Exposure on Prostate Cancer Incidence: An Observational Cohort StudyJournal of Urology, VOL. 178, NO. 5, (2176-2180), Online publication date: 1-Nov-2007. Khastgir J, Khan A and Speakman M (2007) Acute urinary retention: medical management and the identification of risk factors for preventionNature Clinical Practice Urology, 10.1038/ncpuro0860, VOL. 4, NO. 8, (422-431), Online publication date: 1-Aug-2007. SHI T, GAIVIN R, MCCUNE D, GUPTA M and PEREZ D (2008) Dominance of the α 1 B -Adrenergic Receptor and its Subcellular Localization in Human and TRAMP Prostate Cancer Cell Lines Journal of Receptors and Signal Transduction, 10.1080/10799890601087487, VOL. 27, NO. 1, (27-45), Online publication date: 1-Jan-2007. Roehrborn C (2006) Three months' treatment with the α1-blocker alfuzosin does not affect total or transition zone volume of the prostateProstate Cancer and Prostatic Diseases, 10.1038/sj.pcan.4500849, VOL. 9, NO. 2, (121-125), Online publication date: 1-Jun-2006. Novara G, Galfano A, Berto R, Ficarra V, Navarrete R and Artibani W (2006) Inflammation, Apoptosis, and BPH: What is the Evidence?European Urology Supplements, 10.1016/j.eursup.2006.02.003, VOL. 5, NO. 4, (401-409), Online publication date: 1-Apr-2006. Chuang Y, Huang C, Kang H, Chiang P, Demiguel F, Yoshimura N and Chancellor M (2018) Novel Action of Botulinum Toxin on the Stromal and Epithelial Components of the Prostate GlandJournal of Urology, VOL. 175, NO. 3, (1158-1163), Online publication date: 1-Mar-2006. Michel M and Vrydag W (2009) α 1 -, α 2 - and β-adrenoceptors in the urinary bladder, urethra and prostate British Journal of Pharmacology, 10.1038/sj.bjp.0706619, VOL. 147, NO. S2, (S88-S119), Online publication date: 1-Feb-2006. Soh B, Lee J and Chung B (2006) The Changing Pattern of Serum Prostate Specific Antigen in Patients with Benign Prostatic Hyperplasia after Combined Treatment with Finasteride and α-blockers: the 3 Year Follow-up DataKorean Journal of Urology, 10.4111/kju.2006.47.4.372, VOL. 47, NO. 4, (372), . Alberti C, Chiapello G, Bernardi D, Mediago M and Arena G (2018) Quinazoline α1-Blockers: Are there any News about their Efficacy in Inhibiting Prostate Tumor Growth?Urologia Journal, 10.1177/039156030607300402, VOL. 73, NO. 4, (307-311), Online publication date: 1-Jan-2006. Fernando M and Heaney A (2005) α1-Adrenergic Receptor Antagonists: Novel Therapy for Pituitary AdenomasMolecular Endocrinology, 10.1210/me.2004-0471, VOL. 19, NO. 12, (3085-3096), Online publication date: 1-Dec-2005. SHARIAT S, ASHFAQ R, ROEHRBORN C, SLAWIN K and LOTAN Y (2018) EXPRESSION OF SURVIVIN AND APOPTOTIC BIOMARKERS IN BENIGN PROSTATIC HYPERPLASIAJournal of Urology, VOL. 174, NO. 5, (2046-2050), Online publication date: 1-Nov-2005. Chiang C, Son E and Wu G (2005) Oral treatment of the TRAMP mice with doxazosin suppresses prostate tumor growth and metastasisThe Prostate, 10.1002/pros.20260, VOL. 64, NO. 4, (408-418), Online publication date: 1-Sep-2005. MINNERY C and GETZENBERG R (2018) BENIGN PROSTATIC HYPERPLASIA CELL LINE VIABILITY AND MODULATION OF JM-27 BY DOXAZOSIN AND IBUPROFENJournal of Urology, VOL. 174, NO. 1, (375-379), Online publication date: 1-Jul-2005. Tahmatzopoulos A, Lagrange C, Zeng L, Mitchell B, Conner W and Kyprianou N (2005) Effect of terazosin on tissue vascularity and apoptosis in transitional cell carcinoma of bladderUrology, 10.1016/j.urology.2004.12.015, VOL. 65, NO. 5, (1019-1023), Online publication date: 1-May-2005. Andersson K (2005) Mode of action of α-adrenoceptor antagonists in the treatment of lower urinary tract symptomsCurrent Prostate Reports, 10.1007/s11918-996-0012-1, VOL. 3, NO. 1, (28-33), Online publication date: 1-Mar-2005. VELA-NAVARRETE R, ESCRIBANO-BURGOS M, FARRÉ A, GARCÍA-CARDOSO J, MANZARBEITIA F and CARRASCO C (2018) SERENOA REPENS TREATMENT MODIFIES BAX/BCL-2 INDEX EXPRESSION AND CASPASE-3 ACTIVITY IN PROSTATIC TISSUE FROM PATIENTS WITH BENIGN PROSTATIC HYPERPLASIAJournal of Urology, VOL. 173, NO. 2, (507-510), Online publication date: 1-Feb-2005. Keledjian K, Garrison J and Kyprianou N (2005) Doxazosin inhibits human vascular endothelial cell adhesion, migration, and invasionJournal of Cellular Biochemistry, 10.1002/jcb.20240, VOL. 94, NO. 2, (374-388), Online publication date: 1-Feb-2005. Gandour-Edwards R, Mack P, deVere-White R and Gumerlock P (2004) Abnormalities of apoptotic and cell cycle regulatory proteins in distinct histopathologic components of benign prostatic hyperplasiaProstate Cancer and Prostatic Diseases, 10.1038/sj.pcan.4500749, VOL. 7, NO. 4, (321-326), Online publication date: 1-Dec-2004. AUSTIN P, COOK B, NIEDERHOFF R, MANSON S, COPLEN D and WEINTRAUB S (2018) INHIBITION OF MITOGENIC SIGNALING AND INDUCTION OF APOPTOSIS IN HUMAN BLADDER SMOOTH MUSCLE CELLS TREATED WITH DOXAZOSINJournal of Urology, VOL. 172, NO. 4 Part 2, (1662-1666), Online publication date: 1-Oct-2004. Doggrell S (2005) After ALLHAT: doxazosin for the treatment of benign prostatic hyperplasiaExpert Opinion on Pharmacotherapy, 10.1517/14656566.5.9.1957, VOL. 5, NO. 9, (1957-1964), Online publication date: 1-Sep-2004. Hegarty P, Watson R, Hegarty N, Coffey R and Fitzpatrick J (2004) Pressure effects on cellular systems: Is there a link with benign prostatic hyperplasia?Urology, 10.1016/j.urology.2004.03.037, VOL. 64, NO. 2, (195-200), Online publication date: 1-Aug-2004. Walden P, Globina Y and Nieder A (2004) Induction of anoikis by doxazosin in prostate cancer cells is associated with activation of caspase-3 and a reduction of focal adhesion kinaseUrological Research, 10.1007/s00240-003-0365-7, VOL. 32, NO. 4, (261-265), Online publication date: 1-Aug-2004. Tahmatzopoulos A, Rowland R and Kyprianou N (2005) The role of α-blockers in the management of prostate cancerExpert Opinion on Pharmacotherapy, 10.1517/14656566.5.6.1279, VOL. 5, NO. 6, (1279-1285), Online publication date: 1-Jun-2004. Tahmatzopoulos A and Kyprianou N (2004) Apoptotic impact of ?1-blockers on prostate cancer growth: A myth or an inviting reality?The Prostate, 10.1002/pros.10357, VOL. 59, NO. 1, (91-100), Online publication date: 1-Apr-2004. Power R and Fitzpatrick J (2004) Medical Treatment of BPH: An Update on ResultsEAU Update Series, 10.1016/j.euus.2004.01.003, VOL. 2, NO. 1, (6-14), Online publication date: 1-Mar-2004. Kirby R, Quinn S, Mallen S and Jensen D (2004) Doxazosin controlled release vs tamsulosin in the management of benign prostatic hyperplasia: an efficacy analysisInternational Journal of Clinical Practice, 10.1111/j.1368-5031.2004.0031.x, VOL. 58, NO. 1, (6-10) Kaplan S (2018) Benign Prostatic HyperplasiaJournal of Urology, VOL. 171, NO. 1, (538-544), Online publication date: 1-Jan-2004. Michel M (2003) Protecting Bladder Function and Reducing Disease ProgressionEuropean Urology Supplements, 10.1016/j.eursup.2003.09.003, VOL. 2, NO. 7, (13-18), Online publication date: 1-Nov-2003. KYPRIANOU N (2018) Doxazosin and Terazosin Suppress Prostate Growth by Inducing Apoptosis: Clinical SignificanceJournal of Urology, VOL. 169, NO. 4, (1520-1525), Online publication date: 1-Apr-2003. Thorpe A and Neal D (2003) Benign prostatic hyperplasiaThe Lancet, 10.1016/S0140-6736(03)13073-5, VOL. 361, NO. 9366, (1359-1367), Online publication date: 1-Apr-2003. KELEDJIAN K and KYPRIANOU N (2018) Anoikis Induction by Quinazoline Based α1-Adrenoceptor Antagonists in Prostate Cancer Cells: Antagonistic Effect of Bcl-2Journal of Urology, VOL. 169, NO. 3, (1150-1156), Online publication date: 1-Mar-2003. Mudiyala R and Ahmed A Effect of Terazosin on Clinical Benign Prostatic Hyperplasia in Older AdultsJournal of the American Geriatrics Society, 10.1046/j.1532-5415.2003.51120.x, VOL. 51, NO. 3, (424-426) Staack A, Kassis A, Olshen A, Wang Y, Wu D, Carroll P, Grossfeld G, Cunha G and Hayward S (2003) Quantitation of apoptotic activity following castration in human prostatic tissue in vivoThe Prostate, 10.1002/pros.10179, VOL. 54, NO. 3, (212-219), Online publication date: 15-Feb-2003. PAN S, GUH J, HUANG Y, CHERN J, CHOU J and TENG C (2018) Identification of Apoptotic and Antiangiogenic Activities of Terazosin in Human Prostate Cancer and Endothelial CellsJournal of Urology, VOL. 169, NO. 2, (724-729), Online publication date: 1-Feb-2003. Closset J and Reiter E (2003) Prostate Handbook of Cell Signaling, 10.1016/B978-012124546-7/50711-7, (591-605), . Michel M (2002) Potential Role of α1-Adrenoceptors in the Aetiology of LUTSEuropean Urology Supplements, 10.1016/S1569-9056(02)00118-5, VOL. 1, NO. 9, (5-13), Online publication date: 1-Nov-2002. Sun Y, MaLossi J, Jacobs S and Chai T (2002) Effect of doxazosin on stretch-activated adenosine triphosphate release in bladder urothelial cells from patients with benign prostatic hyperplasiaUrology, 10.1016/S0090-4295(02)01710-7, VOL. 60, NO. 2, (351-356), Online publication date: 1-Aug-2002. Anglin I, Glassman D and Kyprianou N (2002) Induction of prostate apoptosis by α1-adrenoceptor antagonists: mechanistic significance of the quinazoline componentProstate Cancer and Prostatic Diseases, 10.1038/sj.pcan.4500561, VOL. 5, NO. 2, (88-95), Online publication date: 1-Jun-2002. Das A, Leggett R, Whitbeck C, Eagen G and Levin R (2002) Effect of Doxazosin on rat urinary bladder function after partial outlet obstructionNeurourology and Urodynamics, 10.1002/nau.10045, VOL. 21, NO. 2, (160-166), Online publication date: 1-Mar-2002. Akduman B and Crawford E (2001) Terazosin, doxazosin, and prazosin: current clinical experienceUrology, 10.1016/S0090-4295(01)01302-4, VOL. 58, NO. 6, (49-54), Online publication date: 1-Dec-2001. Boyle P, Robertson C, Manski R, Padley R and Roehrborn C (2001) Meta-analysis of randomized trials of terazosin in the treatment of benign prostatic hyperplasiaUrology, 10.1016/S0090-4295(01)01344-9, VOL. 58, NO. 5, (717-722), Online publication date: 1-Nov-2001. Ilio K, Park I, Pins M, Kozlowski J and Lee C (2001) Apoptotic activity of doxazosin on prostate stroma in vitro is mediated through an autocrine expression of TGF-?1The Prostate, 10.1002/pros.1091, VOL. 48, NO. 3, (131-135), Online publication date: 1-Aug-2001. Keledjian K, Borkowski A, Kim G, Isaacs J, Jacobs S and Kyprianou N (2001) Reduction of human prostate tumor vascularity by the ?1-adrenoceptor antagonist terazosinThe Prostate, 10.1002/pros.1083, VOL. 48, NO. 2, (71-78), Online publication date: 1-Jul-2001. Amadesi S, Varani K, Spisani L, Daniele C, Turini A, Agnello G, Zamboni P, Borea P and Geppetti P (2001) Comparison of prazosin, terazosin and tamsulosin: Functional and binding studies in isolated prostatic and vascular human tissuesThe Prostate, 10.1002/pros.1067, VOL. 47, NO. 4, (231-238), Online publication date: 1-Jun-2001. Cuellar D and Kyprianou N (2001) Future concepts in the medical therapy of benign prostatic hyperplasiaCurrent Opinion in Urology, 10.1097/00042307-200101000-00004, VOL. 11, NO. 1, (27-33), Online publication date: 1-Jan-2001. Chapple C (2001) Alpha adrenoceptor antagonists in the year 2000: is there anything new?Current Opinion in Urology, 10.1097/00042307-200101000-00002, VOL. 11, NO. 1, (9-16), Online publication date: 1-Jan-2001. SHIBATA Y, FUKABORI Y, ITO K, SUZUKI K and YAMANAKA H (2018) COMPARISON OF HISTOLOGICAL COMPOSITIONS AND APOPTOSIS IN CANINE SPONTANEOUS BENIGN PROSTATIC HYPERPLASIA TREATED WITH ANDROGEN SUPPRESSIVE AGENTS CHLORMADINONE ACETATE AND FINASTERIDEJournal of Urology, VOL. 165, NO. 1, (289-293), Online publication date: 1-Jan-2001. Lin V, Benaim E and McConnell J (2001) Alpha-blockade downregulates myosin heavy chain gene expression in human benign prostatic hyperplasiaUrology, 10.1016/S0090-4295(00)00842-6, VOL. 57, NO. 1, (170-175), Online publication date: 1-Jan-2001. Glassman D, Chon J, Borkowski A, Jacobs S and Kyprianou N (2001) Combined effect of terazosin and finasteride on apoptosis, cell proliferation, and transforming growth factor-? expression in benign prostatic hyperplasiaThe Prostate, 10.1002/1097-0045(200101)46:1 3.0.CO;2-U, VOL. 46, NO. 1, (45-51), Online publication date: 1-Jan-2001. Vacherot F, Azzouz M, Gil-Diez-de-Medina S, Colombel M, De La Taille A, Lefr�re Belda M, Abbou C, Raynaud J and Chopin D (2000) Induction of apoptosis and inhibition of cell proliferation by the lipido-sterolic extract ofSerenoa repens (LSESr, Permixon�) in benign prostatic hyperplasiaThe Prostate, 10.1002/1097-0045(20001101)45:3 3.0.CO;2-G, VOL. 45, NO. 3, (259-266), Online publication date: 1-Nov-2000. Michel M, Schäfers R and Goepel M (2002) α-Blockers and lower urinary tract function: more than smooth muscle relaxation?BJU International, 10.1046/j.1464-410X.2000.00094.x, VOL. 86, (23-30), Online publication date: 1-Oct-2000. Griffiths K (2000) Estrogens and prostatic diseaseThe Prostate, 10.1002/1097-0045(20001001)45:2 3.0.CO;2-G, VOL. 45, NO. 2, (87-100), Online publication date: 1-Oct-2000. MARCELLI M, SHAO T, LI X, YIN H, MARANI M, DENNER L, TENG B and CUNNINGHAM G (2000) INDUCTION OF APOPTOSIS IN BPH STROMAL CELLS BY ADENOVIRAL-MEDIATED OVEREXPRESSION OF CASPASE-7The Journal of Urology, 10.1097/00005392-200008000-00077, (518-525), Online publication date: 1-Aug-2000. MARCELLI M, SHAO T, LI X, YIN H, MARANI M, DENNER L, TENG B and CUNNINGHAM G (2018) INDUCTION OF APOPTOSIS IN BPH STROMAL CELLS BY ADENOVIRAL-MEDIATED OVEREXPRESSION OF CASPASE-7Journal of Urology, VOL. 164, NO. 2, (518-525), Online publication date: 1-Aug-2000. Smith P, Rhodes N, Ke Y and Foster C (2000) Modulating effect of estrogen and testosterone on prostatic stromal cell phenotype differentiation induced by noradrenaline and doxazosinThe Prostate, 10.1002/1097-0045(20000701)44:2 3.0.CO;2-3, VOL. 44, NO. 2, (111-117), Online publication date: 1-Jul-2000. Caropreso D and Moon T (2000) α-Blockers: An effective treatment for prostatitis?Current Urology Reports, 10.1007/s11934-000-0050-0, VOL. 1, NO. 2, (148-154), Online publication date: 1-Jun-2000. Kyprianou N and Jacobs S (2000) Induction of apoptosis in the prostate by α1-adrenoceptor antagonists: A novel effect of "Old" drugsCurrent Urology Reports, 10.1007/s11934-000-0042-0, VOL. 1, NO. 2, (89-96), Online publication date: 1-Jun-2000. MARKS L, PARTIN A, EPSTEIN J, TYLER V, SIMON I, MACAIRAN M, CHAN T, DOREY F, GARRIS J, VELTRI R, SANTOS P, STONEBROOK K and deKERNION J (2018) EFFECTS OF A SAW PALMETTO HERBAL BLEND IN MEN WITH SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIAJournal of Urology, VOL. 163, NO. 5, (1451-1456), Online publication date: 1-May-2000. Cal C, Uslu R, Gunaydin G, Ozyurt C and Omay S (2001) Doxazosin: a new cytotoxic agent for prostate cancer?BJU International, 10.1046/j.1464-410x.2000.00607.x, VOL. 85, NO. 6, (672-675) Abrams P (2000) Facts and future lines of research in prostate cancer: concluding remarksBJU International, 10.1046/j.1464-410X.2000.00065.x, VOL. 85, (49-51), Online publication date: 1-Apr-2000. Andersson K (2000) Mode of action of α 1 -adrenoreceptor antagonists in the treatment of lower urinary tract symptoms BJU International, 10.1046/j.1464-410X.2000.00059.x, VOL. 85, (12-18), Online publication date: 1-Apr-2000. Kyprianou N, Chon J and Benning C (2000) Effects of Alpha1-adrenoceptor (?1-AR) antagonists on cell proliferation and apoptosis in the prostate: Therapeutic implications in prostatic diseaseThe Prostate, 10.1002/1097-0045(2000)45:9+ 3.0.CO;2-U, VOL. 45, NO. S9, (42-46), . Boesch S, Dobler G, Ramoner R, Corvin S, Thurnher M, Bartsch G and Klocker H (2000) Effects of ?1-adrenoceptor antagonists on cultured prostatic smooth muscle cellsThe Prostate, 10.1002/1097-0045(2000)45:9+ 3.0.CO;2-Y, VOL. 45, NO. S9, (34-41), . CHON J, BORKOWSKI A, PARTIN A, ISAACS J, JACOBS S and KYPRIANOU N (2018) alpha1-ADRENOCEPTOR ANTAGONISTS TERAZOSIN AND DOXAZOSIN INDUCE PROSTATE APOPTOSIS WITHOUT AFFECTING CELL PROLIFERATION IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIAJournal of Urology, VOL. 161, NO. 6, (2002-2008), Online publication date: 1-Jun-1999. Boesch S, Corvin S, Zhang J, Rogatsch H, Bartsch G and Klocker H (1999) Modulation of the differentiation status of cultured prostatic smooth muscle cells by an ?1-adrenergic receptor antagonistThe Prostate, 10.1002/(SICI)1097-0045(19990601)39:4 3.0.CO;2-8, VOL. 39, NO. 4, (226-233), Online publication date: 1-Jun-1999. Kyprianou N (2002) Induction of Prostate Apoptosis in Response to α1‐Adrenoceptor Antagonists: Therapeutic Significance in Benign Prostatic Hyperplasia and Prostate CancerThe Prostate Journal, 10.1046/j.1525-1411.1999.09918.x, VOL. 1, NO. 2, (73-81), Online publication date: 1-Mar-1999. WALDEN P, GERARDI C and LEPOR H (1999) LOCALIZATION AND EXPRESSION OF THE alpha1A-1, alpha1B AND alpha1D-ADRENOCEPTORS IN HYPERPLASTIC AND NON-HYPERPLASTIC HUMAN PROSTATEThe Journal of Urology, 10.1097/00005392-199902000-00091, (635-640), Online publication date: 1-Feb-1999. WALDEN P, GERARDI C and LEPOR H (2018) LOCALIZATION AND EXPRESSION OF THE alpha1A-1, alpha1B AND alpha1D-ADRENOCEPTORS IN HYPERPLASTIC AND NON-HYPERPLASTIC HUMAN PROSTATEJournal of Urology, VOL. 161, NO. 2, (635-640), Online publication date: 1-Feb-1999. Volume 159Issue 6June 1998Page: 1810-1815 Advertisement Copyright & Permissions© 1998 by American Urological Association, Inc.MetricsAuthor Information NATASHA KYPRIANOU More articles by this author JUAN P. LITVAK More articles by this author ANDREW BORKOWSKI More articles by this author RICHARD ALEXANDER More articles by this author STEPHEN C. JACOBS More articles by this author Expand All Advertisement PDF downloadLoading ...